Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 139 participants.
Also called NCT02622113
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 139 participants
- Sponsor
- Registry
-
NCT02622113
-
- Other papers using this trial's data
- Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02622113. Allocation not applicable; no masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2016-04 (actual). Results posted on 2019-03-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Canagliflozin (TA-7284)
- Intervention (Drug)
- Insulin
- Lead sponsor
- Tanabe Pharma Corporation
Record details
- Record id
cardio:ct-nct02622113- Content hash
f2beae5691c1c06da1d018e9a323b0c931e94d1b78e827db3807a4ca94e208f9